NasdaqGM:BSTC

Stock Analysis Report

Executive Summary

BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for various indications in the United States and internationally.

Snowflake

Fundamentals

Flawless balance sheet with proven track record.

Risks

  • BioSpecifics Technologies is covered by less than 3 analysts.

Share Price & News

How has BioSpecifics Technologies's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-0.9%

BSTC

0.6%

US Biotechs

-0.6%

US Market


1 Year Return

-1.3%

BSTC

-11.2%

US Biotechs

0.7%

US Market

BSTC outperformed the Biotechs industry which returned -10.8% over the past year.

BSTC underperformed the Market in United States of America which returned 0.7% over the past year.


Share holder returns

BSTCIndustryMarket
7 Day-0.9%0.6%-0.6%
30 Day2.7%2.1%4.9%
90 Day0.3%0.4%1.7%
1 Year-1.3%-1.3%-10.4%-11.2%3.0%0.7%
3 Year27.6%27.6%5.9%2.3%44.8%35.4%
5 Year70.1%70.1%3.7%-1.3%62.0%44.3%

Price Volatility Vs. Market

How volatile is BioSpecifics Technologies's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is BioSpecifics Technologies undervalued based on future cash flows and its price relative to the stock market?

19.07x

Price to Earnings (PE) ratio


Intrinsic Value Based on Future Cash Flows

BioSpecifics Technologies's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).

BioSpecifics Technologies's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).


Price Based on Earnings

BioSpecifics Technologies is good value based on earnings compared to the US Biotechs industry average.

BioSpecifics Technologies is overvalued based on earnings compared to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for BioSpecifics Technologies, we can't assess if its growth is good value.


Price Based on Value of Assets

BioSpecifics Technologies is overvalued based on assets compared to the US Biotechs industry average.


Next Steps

Future Growth

How is BioSpecifics Technologies expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

16.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

BioSpecifics Technologies's revenue is expected to grow by 12.8% yearly, however this is not considered high growth (20% yearly).

BioSpecifics Technologies's earnings are expected to grow by 16% yearly, however this is not considered high growth (20% yearly).

BioSpecifics Technologies's revenue growth is expected to exceed the United States of America market average.

BioSpecifics Technologies's earnings growth is expected to exceed the United States of America market average.

BioSpecifics Technologies's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if BioSpecifics Technologies will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has BioSpecifics Technologies performed over the past 5 years?

26.6%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

BioSpecifics Technologies has delivered over 20% year on year earnings growth in the past 5 years.

BioSpecifics Technologies's 1-year earnings growth exceeds its 5-year average (55.6% vs 26.6%)

BioSpecifics Technologies's earnings growth has not exceeded the US Biotechs industry average in the past year (55.6% vs 78.4%).


Return on Equity

BioSpecifics Technologies has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).


Return on Assets

BioSpecifics Technologies used its assets more efficiently than the US Biotechs industry average last year based on Return on Assets.


Return on Capital Employed

BioSpecifics Technologies's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is BioSpecifics Technologies's financial position?


Financial Position Analysis

BioSpecifics Technologies is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

BioSpecifics Technologies has no long term commitments.


Debt to Equity History and Analysis

BioSpecifics Technologies has no debt.

BioSpecifics Technologies has not taken on any debt in the past 5 years.

BioSpecifics Technologies has no debt, it does not need to be covered by operating cash flow.

BioSpecifics Technologies has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet

Low level of unsold assets.

BioSpecifics Technologies has no debt, it does not need to be covered by short term assets.


Next Steps

Dividend

What is BioSpecifics Technologies's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate BioSpecifics Technologies's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate BioSpecifics Technologies's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as BioSpecifics Technologies has not reported any payouts.

Unable to verify if BioSpecifics Technologies's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as BioSpecifics Technologies has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of BioSpecifics Technologies's salary, the management and board of directors tenure and is there insider trading?

12.3yrs

Average board tenure


CEO

Ronald Law (66yo)

0.4yrs

Tenure

0

Dr. Ronald Law, Ph.D., J.D. has been Interim Principal Executive Officer at BioSpecifics Technologies Corp. since April 1, 2019 and served as its Senior Vice President of Business Development since Novembe ...


Board Age and Tenure

12.3yrs

Average Tenure

78yo

Average Age

The average tenure for the BioSpecifics Technologies board of directors is over 10 years, this suggests they are a seasoned and experienced board.


Insider Trading

BioSpecifics Technologies individual insiders have only sold shares in the past 3 months.


Recent Insider Transactions

SellUS$551,67711 Sep 19
Toby Wegman
EntityIndividual
Role
Member of the Board of Directors
Director
Shares10,000
Max PriceUS$55.23
SellUS$26,87410 Jun 19
Jennifer Chao
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares459
Max PriceUS$58.55
SellUS$315,54306 Jun 19
Jennifer Chao
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares5,511
Max PriceUS$58.01
SellUS$352,80005 Jun 19
Patrick Caldwell
EntityIndividual
Role
Chief Financial Officer
Interim Principal Financial Officer
Shares6,000
Max PriceUS$58.80
SellUS$201,23203 Jun 19
Jennifer Chao
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares3,313
Max PriceUS$60.74
SellUS$476,50228 May 19
Mark Wegman
EntityIndividual
Role
Member of the Board of Directors
Director
Shares7,800
Max PriceUS$61.09
SellUS$76,44023 May 19
Mark Wegman
EntityIndividual
Role
Member of the Board of Directors
Director
Shares1,200
Max PriceUS$63.70
SellUS$352,35322 May 19
Toby Wegman
EntityIndividual
Role
Member of the Board of Directors
Director
Shares5,500
Max PriceUS$64.67
SellUS$384,23622 May 19
Mark Wegman
EntityIndividual
Role
Member of the Board of Directors
Director
Shares6,000
Max PriceUS$64.04
SellUS$329,15017 May 19
Paul Gitman
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares5,000
Max PriceUS$65.83

Ownership Breakdown


Management Team

  • Patrick Caldwell (57yo)

    Interim Principal Financial Officer

    • Tenure: 0.4yrs
  • Ronald Law (66yo)

    Interim Principal Executive Officer

    • Tenure: 0.4yrs
  • Carl Valenstein

    Corporate Secretary

    • Tenure: 0yrs

Board Members

  • Paul Gitman (78yo)

    Independent Director

    • Tenure: 29.7yrs
    • Compensation: US$45.00k
  • Michael Schamroth (79yo)

    Independent Director

    • Tenure: 15.3yrs
    • Compensation: US$45.00k
  • Jenn Chao (49yo)

    Independent Director

    • Tenure: 4.4yrs
    • Compensation: US$340.15k
  • Toby Wegman (84yo)

    Director

    • Tenure: 12.3yrs
    • Compensation: US$22.00k
  • Mark Wegman (69yo)

    Director

    • Tenure: 12.3yrs
    • Compensation: US$50.00k

Company Information

BioSpecifics Technologies Corp.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: BioSpecifics Technologies Corp.
  • Ticker: BSTC
  • Exchange: NasdaqGM
  • Founded: 1957
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$423.328m
  • Shares outstanding: 7.33m
  • Website: https://www.biospecifics.com

Number of Employees


Location

  • BioSpecifics Technologies Corp.
  • 35 Wilbur Street
  • Lynbrook
  • New York
  • 11563
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BSTCNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDNov 1991
1B3BST (Boerse-Stuttgart)YesCommon StockDEEURNov 1991

Biography

BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for various indications in the United States and international ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/22 23:33
End of Day Share Price2019/09/20 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.